Prelude Therapeutics Incorporated (PRLD) has announced a public offering of 18.02 million shares priced at $4.44 each, alongside pre-funded warrants for an additional 2.25 million shares at the same price, aiming to raise approximately $90 million. The proceeds will primarily support research and development, working capital, and capital expenditures, with the offering expected to close on April 21, 2026, pending customary conditions.

This capital raise comes as Prelude advances its oncology pipeline, including its lead candidate PRT12396, which recently received FDA IND clearance. The company plans to initiate a Phase 1 study in mid-2026 for patients with polycythemia vera and myelofibrosis. Prelude’s financial position remains solid, with $106 million in cash and equivalents as of December 31, 2025, providing a runway into mid-2027.

For market professionals, the successful completion of this offering could bolster Prelude’s development efforts and potentially enhance its valuation, especially as it moves closer to clinical trials for promising oncology treatments.

Source: nasdaq.com